CClinicalTrials.gg
CompletedNCT03941275Updated Mar 15, 2022

SelectSecure 3830 Lead Imaging

An observational study in Heart Diseases, sponsored by Medtronic Cardiac Rhythm and Heart Failure. Completed at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-03-15.

Sponsored by Medtronic Cardiac Rhythm and Heart Failure · Observational

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
51
Ages
18 Years and older
Sex
All
01

Study summary

This study is designed to collect high-quality shoulder and intracardiac bi-plane fluoroscopic images during two standard arm motions on patients implanted with a market released SelectSecure 3830 lead for the purposes of developing a fracture reliability model.

02

Conditions studied

  • Heart Diseases

Browse trials for

03

In context

Heart Diseases

3,639 studies on the registry are indexed under Heart Diseases; 461 are open to participants now.

This study's enrollment of 51 is below the median of 294 across 1,241 observational studies indexed under Heart Diseases.

Browse Heart Diseases studies →

Lead sponsor

Medtronic Cardiac Rhythm and Heart Failure is the lead sponsor of 239 studies on the registry; 6 are open to participants now.

Of its 19 completed or terminated interventional studies of FDA-regulated products, 17 (89%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Subjects of both genders, 18 years of age and older that are currently implanted with at least one SelectSecure 3830 lead, regardless of device type and who meet all inclusion and no exclusion criteria are eligible for the study.

Inclusion criteria

  • Patients who are at least 18 years of age
  • Patient has a pacing, ICD or CRT system incorporating at least one SelectSecure 3830 lead in the right atrium or right ventricle
  • Patients able and willing to attend imaging session
  • Patients able and willing to give informed consent
  • Pacing capture threshold and pacing impedance of the lead are within normal range at the time of enrollment
  • Patient must be able to accomplish arm flexion and adduction past 90 degrees

Exclusion criteria

Exclusion Criteria:

  • Subjects who require a legally authorized representative to obtain consent
  • Subjects with exclusion criteria required by local law (e.g. age, breastfeeding)
  • Pregnant women, or women of child bearing potential and who are not on a reliable form of birth control
  • Subjects that were implanted with a pacing, ICD, CRT device and/or cardiac leads less than three months ago
05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
51 participants (actual)
Patient registry
No

Groups and cohorts

  • Subjects undergoing bi-plane fluoroscopy

    Diagnostic Test: Bi-plane fluoroscopy

Interventions

  • Diagnostic testBi-plane fluoroscopy

    In vivo acquisition of biplane cine radiographic images of the market released Medtronic SelectSecure 3830 pacing lead

06

What researchers measure

Primary outcomes

  1. Collect high quality shoulder and intracardiac bi-plane fluoroscopic cine images of the SelectSecure 3830 pacing lead.

    Fluoroscopic cine images will be collected in conjunction with a specialized calibration object. When imaging data is processed and analyzed it will characterize the time-varying lead shape changes.

    Time frame: approximately 30 minutes

Secondary outcomes

  1. Acquire accelerometer-based motion data

    During fluoroscopy of the two standard arm motions, accelerometer-based motion data will be collected which will allow matching of arm position with lead shape based on the fluoroscopic images.

    Time frame: approximately 30 minutes

07

Study locations

4 sites
  • Heart Center Research
    Huntsville, Alabama 35801, United States
  • Iowa Heart Center
    West Des Moines, Iowa 50266, United States
  • Associates in Cardiology PA
    Silver Spring, Maryland 20910, United States
  • Lourdes Cardiology Services
    Voorhees, New Jersey 08043, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 15, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03941275
Lead sponsor
Medtronic Cardiac Rhythm and Heart Failure
Responsible party
Sponsor
First posted
May 7, 2019
Start date
May 24, 2019
Primary completion
Nov 3, 2020
Completion
Nov 15, 2021
Last update
Mar 15, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion